2020
Development and validation of a predictive model of drug-resistant genetic generalized epilepsy.
Choi H, Detyniecki K, Bazil C, Thornton S, Crosta P, Tolba H, Muneeb M, Hirsch LJ, Heinzen EL, Sen A, Depondt C, Perucca P, Heiman GA, Adcock J, Andrade D, Cavalleri G, Costello D, Delanty N, Dugan P, Goldstein D, Kwan P, Nascimento F, O’Brien T, Radthke R, Smith P, Thomas R. Development and validation of a predictive model of drug-resistant genetic generalized epilepsy. Neurology 2020, 95: e2150-e2160. PMID: 32759205, PMCID: PMC7713754, DOI: 10.1212/wnl.0000000000010597.Peer-Reviewed Original ResearchConceptsGenetic generalized epilepsyCatamenial epilepsyGeneralized epilepsyPsychiatric conditionsOngoing longitudinal observational studyGeneralized tonic clonicTertiary epilepsy centerNegative prognostic factorCase-control studyLongitudinal observational studyClinical prediction modelAED resistanceTonic clonicPrognostic factorsSeizure typesEpilepsy centersAntiepileptic drugsAbsence seizuresObservational studyOngoing longitudinal studyEpilepsyCase statusAED responsePatientsExternal testing dataset
2006
Topiramate for the treatment of epilepsy and other nervous system disorders
van Passel L, Arif H, Hirsch LJ. Topiramate for the treatment of epilepsy and other nervous system disorders. Expert Review Of Neurotherapeutics 2006, 6: 19-31. PMID: 16466308, DOI: 10.1586/14737175.6.1.19.Peer-Reviewed Original ResearchConceptsPossible neuroprotective agentsTroublesome adverse effectsOral hypoglycemic agentsCognitive side effectsTreatment of epilepsyNervous system disordersNeuropathic painMigraine prophylaxisNeuroprotective agentsHypoglycemic agentsSystem disordersSide effectsBroad-spectrum efficacyBipolar disorderLow dosesPsychiatric conditionsTopiramateSubstance dependenceAdverse effectsEpilepsyDisordersEfficacySpectrum efficacyMonotherapyProphylaxis